Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054163 | 0.91 | NOD2 (0.55) | F10NOD2NOD1CCR2MAPT | |
| SCHEMBL832448 | 0.89 | F10 (0.61) | F10NOD2NOD1CCR2LMNA | |
| SCHEMBL12930106 | 0.87 | NOD2 (0.58) | F10NOD2NOD1CCR2MAPT | |
| SCHEMBL939884 | 0.86 | F10 (0.52) | F10NOD2NOD1CCR2LMNA | |
| SCHEMBL940391 | 0.85 | F10 (0.54) | F10NOD2NOD1CCR2LMNA | |
| SCHEMBL941399 | 0.85 | F10 (0.54) | F10NOD2NOD1CCR2LMNA | |
| SCHEMBL974474 | 0.85 | CCR2 (0.69) | F10CCR2PPARG | |
| SCHEMBL3571653 | 0.84 | NOD2 (0.67) | F10NOD2NOD1PPARG | |
| SCHEMBL925921 | 0.84 | F10 (0.51) | F10NOD2NOD1CCR2MAPT | |
| SCHEMBL3578136 | 0.84 | PPARG (0.54) | F10NOD2NOD1CCR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557134-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080255131-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | US | disclosed |
| US-7407950-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | TRPV1, TRPV5, TRPA1 | F10 759/4885NOD2 293/4885NOD1 199/4885 |
| US-20080255131-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | TRPV1, TRPV3, TRPV2 | F10 2085/4885NOD2 264/4885NOD1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.